title: Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design.
abstract: With the event of new Molecular targets, clinical trial design requirements to perform these trials are changing. This paper discusses some of the considerations that need to be taken into account when designing a trial, including those trials that assess combinations of targets.
authors.affiliation: Erasmus University Medical Center, Daniel den Hoed Cancer Center, s' Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. j.verweij@erasmusmc.nl
authors.forename: Jaap
authors.initials: J
authors.lastname: Verweij
authors.forename: Maja
authors.initials: M
authors.lastname: de Jonge
authors.forename: Ferry
authors.initials: F
authors.lastname: Eskens
authors.forename: Stefan
authors.initials: S
authors.lastname: Sleijfer
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D057285:Precision Medicine; D012107:Research Design
chemical_list: D000970:Antineoplastic Agents